Table 1.
Baseline characteristics of participants.
| Total n = 288 | Metformin n = 140 | Placebo n = 148 | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 29.1 ± 4.4 | 29.4 ± 4.5 | 28.9 ± 4.3 |
| Weight (kg) | 80.8 ± 18.8 | 82.2 ± 19.1 | 79.5 ± 18.5 |
| BMI (kg/m2) | 28.8 ± 6.6 | 29.4 ± 6.6 | 28.3 ± 6.6 |
| Parity (%) | |||
| 0 | 61.5 | 63.6 | 59.5 |
| 1 | 30.6 | 30.7 | 30.4 |
| 2 | 6.6 | 4.3 | 8.8 |
| 3 | 1.4 | 1.4 | 1.4 |
| Smoking (%) | 8.1 | 10.7 | 5.6 |
| Caucasian ethnicity (%) | 97.6 | 96.4 | 98.6 |
| Hypothyroidism prior to inclusion (%) | 4.5 | 4.3 | 4.7 |
| Metformin treatment at conception (%) | 30.6 | 31.4 | 29.7 |
| Gestational age at inclusion (days) | 73 ± 14 | 73 ± 14 | 72 ± 14 |
| Positive TPO-ab (%) | 7.1 | 7.4 | 6.9 |
| Clinical characteristics | |||
| Systolic blood pressure (mm Hg) | 118 ± 12 | 119 ± 13 | 117 ± 12 |
| Diastolic blood pressure (mm Hg) | 73 ± 11 | 74 ± 12 | 72 ± 10 |
| Glucose fasting (mmol/L) | 4.6 ± 0.5 | 4.6 ± 0.5 | 4.7 ± 0.6 |
| Glucose 2h (mmol/L) | 5.7 ± 1.6 | 5.6 ± 1.5 | 5.8 ± 1.7 |
Data presented as mean ± SD or n (%) as appropriate.
None of the comparisons between the groups showed statistically significant difference (p-value < 0.05).